Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001472375-23-000090
Filing Date
2023-06-09
Accepted
2023-06-09 12:46:24
Documents
54
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2023 ixform10k.htm   iXBRL 10-K 464666
2 CERTIFICATION exhibit31-1.htm EX-31.1 10810
3 CERTIFICATION exhibit31-2.htm EX-31.2 10824
4 CERTIFICATION exhibit32-1.htm EX-32.1 4141
5 CERTIFICATION exhibit32-2.htm EX-32.2 4140
6 regenerexlogo.gif GRAPHIC 5716
  Complete submission text file 0001472375-23-000090.txt   2556404

Data Files

Seq Description Document Type Size
7 SCHEMA DOCUMENT rgpx-20230331.xsd EX-101.SCH 22441
8 CALCULATION LINKBASE DOCUMENT rgpx-20230331_cal.xml EX-101.CAL 32951
9 DEFINITION LINKBASE DOCUMENT rgpx-20230331_def.xml EX-101.DEF 52381
10 LABELS LINKBASE DOCUMENT rgpx-20230331_lab.xml EX-101.LAB 174859
11 PRESENTATION LINKBASE DOCUMENT rgpx-20230331_pre.xml EX-101.PRE 144554
48 EXTRACTED XBRL INSTANCE DOCUMENT ixform10k_htm.xml XML 223788
Mailing Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108
Business Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108 305-927-5191
REGENEREX PHARMA, INC. (Filer) CIK: 0001357878 (see all company filings)

EIN.: 980479983 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-K | Act: 34 | File No.: 000-53230 | Film No.: 231004569
SIC: 2834 Pharmaceutical Preparations